Lenalidomide Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, which triggers the ubiquitination and subsequent proteasomal degradation of transcription factors Ikaros and Aiolos. This molecular event leads to anti‑angiogenic effects, modulation of cytokine production, enhanced immune cell activity, and inhibition of malignant cell proliferation, collectively contributing to its antineoplastic activity.

The specific dose of Lenalidomide Grindeks is individualized and must be determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Prescribers follow approved dosing guidelines and adjust the regimen as needed; patients should not alter the dose without medical advice.

Lenalidomide Grindeks is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception before, during, and after treatment. The drug is also not recommended while breastfeeding, as it may be excreted in breast milk and affect the infant.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory imide drug (IMiD) class, but lenalidomide is generally more potent and has a more favorable safety profile, especially regarding peripheral neuropathy. Lenalidomide also exhibits stronger anti‑angiogenic and immune‑activating effects, leading to broader use in multiple myeloma and specific myelodysplastic syndromes, whereas thalidomide is often reserved for cases where lenalidomide is unsuitable.

Lenalidomide Grindeks should be stored at ambient temperature, preferably below 25 °C, in its original blister or bottle to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms. No refrigeration is required for this oral formulation.

Lenalidomide Grindeks is administered orally as a tablet taken with water. The tablet is usually taken on an empty stomach, at least one hour before or two hours after meals, unless the prescribing information states otherwise. Patients should follow the exact schedule provided by their healthcare professional and not skip doses without consulting their prescriber.

The most serious risks include severe neutropenia or thrombocytopenia that can lead to infection or bleeding, venous thromboembolism (blood clots), tumor lysis syndrome, secondary primary malignancies, and severe allergic reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for blood counts, signs of clotting, and any unexpected skin or systemic reactions, and report concerns promptly to their clinician.

Lenalidomide Grindeks should not be used by pregnant women, women who are not using effective contraception, or individuals with known hypersensitivity to lenalidomide or any of its excipients. It is also contraindicated in patients with severe renal impairment unless dose adjustments are made under strict medical supervision, and in those with uncontrolled active infections.